Sana Biotechnology presented its Type 1 diabetes strategy at Morgan Stanley’s 24th Annual Global Healthcare Conference on Monday, Sept. 14, 2026. CEO Steve Harr said the firm aims to file an IND and start a Phase I/II trial for its SC451 iPSC‑derived pancreatic islet program by the end of 2024, with patient dosing expected in early 2025 and early safety data due in 2025.
The company reported a cash balance of $160 million at the end of Q2 2024, which management believes will fund operations into the middle of 2025 at current burn rates. A $25 million equity investment from Mayo Clinic earlier in 2024 was highlighted as a strategic partnership, though the deal was executed at a premium valuation.
Sana’s stock hovered around $3.15, with a market capitalization of $967 million. The shares have fallen 21% year‑to‑date and nearly 17% over the past week. Analyst price targets range from $6 to $12, and the stock’s beta stands at 2.13.
Technical progress includes the creation of a genomically stable GMP master cell bank, achieved by knocking out two genes and knocking in two others. Non‑clinical GLP toxicology, biodistribution, efficacy and genomic stability studies are preliminarily complete, and a safety switch is built into the cell design.
In a separate update, the CAR‑T program SG293, based on Fusogen technology, now targets a data window in the first half of 2027, later than the previously anticipated late‑2024 timeline. The program will first address CD19‑positive non‑Hodgkin lymphoma before moving to a BCMA‑targeted indication.
Harr referenced a patient case, UP421, in which engineered cells survived 14 months without immunosuppression. He emphasized that the durability of these cells is expected, stating that any loss due to immune response would be disclosed.
Overall, Sana Biotechnology is positioning its platform as a scalable, cell‑engineering approach to address high‑prevalence diseases, with Type 1 diabetes as the flagship indication.
